Golidocitinib is a targeted therapy indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (rPTCL). Following the implementation of the 2025 National Medical Insurance Catalog, its price has been substantially reduced. At present, each box (30 capsules) is priced at approximately 2,215 US dollars, with the annual treatment cost falling to within 14,409 US dollars, which has significantly eased the financial burden on patients.
Pricing Changes Before and After National Medical Insurance Inclusion
Price before insurance inclusion: Approximately 4,485 RMB per box (30 capsules), with the annual treatment cost reaching as high as around 43,228 US dollars.
Price after insurance inclusion
Since the official implementation of the revised 2025 National Medical Insurance Catalog in January 2025, the price per box has dropped to about 2,215 US dollars, representing a price reduction of over 50%. The annual treatment cost is now controlled within 14,409 US dollars.
Impacts of National Medical Insurance Reimbursement
Having been included in the scope of national medical insurance reimbursement, the drug allows patients to claim a portion of the expenses through medical insurance, which has drastically lowered their out-of-pocket proportion.
For ordinary households, this has effectively alleviated the financial strain of anti-cancer medication and enabled more patients to afford long-term treatment.
Basic Drug Information
Golidocitinib Capsules are primarily indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma, a rare type of hematologic malignancy.
As a targeted therapy, it acts on specific cancer cell signaling pathways and has relatively mild adverse effects. However, during clinical use, patients are required to follow the doctor’s advice to monitor treatment efficacy and safety.
